Core Points - Haofan Bio (301393.SZ) announced the approval of changes in the use of raised funds and the completion of certain fundraising projects during its board and supervisory meetings [1] Group 1: Fund Utilization Changes - The project "Suzhou Haofan Bio Co., Ltd. 100kg/year peptide and protein reagent R&D and production and headquarters construction project (Phase I)" has reached a state of intended use, and the remaining funds will be used to supplement working capital [1] - Due to external policy changes and the current operational needs, the company plans to change the use of a total of 49,696.68 million yuan of raised funds from the "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" to the "Huaian Haofan production base construction project" [1] - The "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" are proposed to be completed, with the remaining funds after the changes being used to supplement working capital [1] Group 2: Project Timeline Adjustments - To ensure the safe, rapid, and orderly advancement of capacity construction, the company has decided to phase the construction of the production line for the Huaian Haofan production base, extending the timeline to reach the intended use state until December 2028 [1]
昊帆生物：拟变更部分募集资金用途、部分募投项目结项和部分募投项目延期